Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/28938
Title: Cluster headache in adults.
Austin Authors: Ray, Jason C ;Stark, Richard J;Hutton, Elspeth J
Affiliation: Department of Neurology, Alfred Hospital, Melbourne, Victoria, Australia..
Neurology
Department of Neuroscience, Monash University, Melbourne, Victoria, Australia.. ..
Issue Date: Feb-2022
Date: 2022
Publication information: Australian prescriber 2022; 45(1): 15-20
Abstract: Cluster headache is characterised by attacks of very severe, unilateral headache lasting 15-180 minutes, up to eight times per day. The attacks are associated with cranial autonomic symptoms on the same side and a sense of agitation or restlessness First-line acute abortive treatments include intranasal or subcutaneous sumatriptan or high-flow oxygen. Neuromodulation may benefit some patients First-line preventive therapy is high-dose verapamil. Close monitoring is required for the adverse effect of arrhythmia There are several emerging therapies that have either proven efficacy, or possible benefit for cluster headache. They include drugs aimed at the calcitonin gene-related peptide.
URI: https://ahro.austin.org.au/austinjspui/handle/1/28938
DOI: 10.18773/austprescr.2022.004
ORCID: https://orcid.org/0000-0003-4833-5507
https://orcid.org/0000-0002-8543-7767
https://orcid.org/0000-0002-1637-9700
Journal: Australian prescriber
PubMed URL: 35233134
PubMed URL: https://pubmed.ncbi.nlm.nih.gov/35233134/
ISSN: 0312-8008
Type: Journal Article
Subjects: calcitonin gene-related peptide
cluster headache
trigeminal autonomic cephalalgias
triptans
Appears in Collections:Journal articles

Show full item record

Page view(s)

26
checked on Nov 8, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.